Nature Medicine has selected promising clinical studies for 2026, emphasizing long-lasting vaccines and innovative treatments. Key areas include tuberculosis, HIV, long Covid, stem cells, and cholesterol. These developments could transform the fight against global diseases.
Nature Medicine has highlighted five clinical studies poised to advance medicine in 2026. The first is a phase 3 trial for a long-lasting tuberculosis vaccine involving 20,000 participants in South Africa, Kenya, Malawi, Zambia, and Indonesia. In 2023, tuberculosis caused 11 million cases and 1.25 million deaths, with the current vaccine losing effectiveness in adolescence, a high-risk period. Results are expected in three years, marking the most promising development in nearly a century.
For HIV, the RIO study by Rockefeller, Imperial, and Oxford universities tests a six-month antibody cocktail. After five months off antivirals, 75% of participants maintained undetectable viral loads, with some for up to two years, compared to 11% in the placebo group.
Addressing long Covid, which causes fatigue and cognitive issues, the UK's National Institute for Health allocated 6.8 million pounds in 2021. The research targets blood vessels, inflammation, and clots, with findings due in 2026.
The Nest trial uses bone marrow stem cells injected through nasal vessels to repair brain damage. Building on a 2010 vision study, it has treated about 200 individuals, yielding significant improvements in Alzheimer's, amyotrophic lateral sclerosis, Parkinson's, multiple sclerosis, and traumatic encephalopathy. The process is safe and takes under an hour.
Finally, the Lp(a)Horizon trial evaluates pelacarsen against Lp(a) lipoprotein, genetically linked to heart attacks and strokes. Involving 7,000 global participants, it reduces levels by 80%, with results in 2026 potentially addressing the world's leading cause of death.
